a non-viral approach to genetically modify CAR-T cells. Shedding the CAR-T projects means Merck can concentrate on the development of its PD-L1 inhibitor Bavencio (avelumab) – partnered with ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close. Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

(RTTNews) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational ...

Also Read: Merck’s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer. At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not ...

DOLLARS vs HORSEPOWER. Where is the sweet spot? Worth It- MODS! (Porsche GT3RS) In this new video from Vin Anatra on YouTube, he explores that tipping point by comparing a stock Porsche 997 GT3 RS ...

The strength of Schonfeld et al is that it combines 4 large prospective trials that included a huge number of patients and cancers. A limitation is that although the women were part of prospective ...